Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-9626
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$32.10 million
Profitability
Miscellaneous
Employees138
OptionableOptionable
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics Inc (NASDAQ:MCRB) released its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.03. The biotechnology company earned $9.06 million during the quarter, compared to analyst estimates of $23.43 million. Seres Therapeutics had a negative net margin of 515.16% and a negative return on equity of 1,584.66%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
4 brokerages have issued twelve-month price targets for Seres Therapeutics' shares. Their predictions range from $15.00 to $16.00. On average, they expect Seres Therapeutics' share price to reach $15.3333 in the next twelve months. This suggests a possible upside of 168.5% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.
What is the consensus analysts' recommendation for Seres Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.
Has Seres Therapeutics been receiving favorable news coverage?
Media stories about MCRB stock have trended very positive on Tuesday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Seres Therapeutics earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX) and G1 Therapeutics (GTHX).
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Dr. Roger James Pomerantz M.D., F.A.C.P., Chairman, Pres & CEO (Age 61)
- Mr. Eric D. Shaff, Exec. VP, Chief Operating & Financial Officer and Treasurer (Age 42)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 57)
- Dr. David N. Cook, Exec. VP of R&D and Chief Scientific Officer (Age 60)
- Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $5.71.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $233.29 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.
What is Seres Therapeutics' official website?
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.
MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
